WTF? 😬 @fmartinezvalle què en penses? 👌
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
CC @Aravinddr3
RT @LuisZuritaG: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperin…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study - The Lancet Rheumatology https://t.co/ExMTkwgguS
anakinra(アナキンラ・IL-1阻害薬)が新型コロナウイルスによるARDSに有効か? アクテムラと同様、関節リウマチの治療薬として使われていて、過剰な免疫応答を抑制するのに効果的なようです。 コホート研究なので、ランダム化比較試験 (RCT)でどうなのかが気になります! https://t.co/CfMaaipasF
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Anakinra in moderate-severe #COVID19 improves survival! @SanRaffaeleMI
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @JeremyTurling: Another potential pathway to block the hyper inflammatory response in COVID-19. #COVID19 #CytokineStorm #IL1Blockade
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Another potential pathway to block the hyper inflammatory response in COVID-19. #COVID19 #CytokineStorm #IL1Blockade
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @AbbateAntonio: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper…
RT @AbbateAntonio: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @KrishPatelMD: Important inital work, though need more data regarding anti-cytokines in #COVID19. Please join our ongoing effort @Swedis…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @AbbateAntonio: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @AbbateAntonio: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
組換え型インターロイキン-1受容体拮抗薬アナキンラを高用量使用した29人中21人が炎症蛋白質の低下と呼吸機能の改善が見られた. 1日目の生存率は、アナキンラ高用量群で90%、標準治療群で56%であった(p=0-009)
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Interleukin-1 blockade with high-dose #anakinra in patients with #COVID19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/dqQpcljWM2
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @syinvesting: #COVID19 $SOBI First data from Italy of IL-1 blockade in patients with #ARDS & hyperinflammation. High-dose IV anakinra w…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Important inital work, though need more data regarding anti-cytokines in #COVID19. Please join our ongoing effort @Swedish to capture real world data for anti-cytokines in the @reactcovid19 registry. We are accruing pts daily and encourage broad multi-ctr
Another anti-IL drug, although in this case an anti-IL1.
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @syinvesting: #COVID19 $SOBI First data from Italy of IL-1 blockade in patients with #ARDS & hyperinflammation. High-dose IV anakinra w…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @DrugVacCovid19: Topol先生もアナキンラのスタディを紹介。アナキンラ投与群では各種バイオマーカーも改善傾向とのこと。 https://t.co/YMHKML6lcB
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
@ccarballo50 que opina de este estudio???https://t.co/i5npkJaRSL
دراسة لقت إن دوا روماتويد اسمه اناكينرا بيقلل الوفيات في الحالات الشديدة للكورونا... طبعا كل دراسة لازم تقول محتاجين دراسات أكتر
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
Topol先生もアナキンラのスタディを紹介。アナキンラ投与群では各種バイオマーカーも改善傾向とのこと。
RT @ABsteward: In this small retrospective cohort study @TheLancetRheum of patients with #COVID19 and ARDS managed with non-invasive ventil…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study - The Lancet Rheumatology https://t.co/RErYAIpgeX
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
@KaplanBen_Fr @Le___Doc @DamienERNST1 @Karolien1231
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, ARDS and hyperinflammation: a retrospective cohort study - 29 patients/ high dose Anakinra, 16 patients; standard therapy. Better outcome in mortality, ventilator, LOS with Anakinra
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
Interesting!
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…